Notice is hereby given that the Office of Research Integrity (ORI) has taken final action in the following case: Julie Mass[egrave], Pennsylvania State University (PSU): Based on an assessment conducted by the Pennsylvania State University College of Medicine (PSU-COM) and the Respondent's admission, ORI and PSU found that Ms. Julie Mass[egrave], former postdoctoral scholar, PSU-COM, engaged in research misconduct in research supported by National Cancer Institute (NCI), National Institutes of Health (NIH), grant 4 R00 CA138498. ORI found that the Respondent knowingly engaged in research misconduct by falsifying and/or fabricating Western blot data and analyses that were including in the following manuscript: <bullet> "Cellular invasion following p120-catenin loss is mediated by AP-1, ITGA2 and MMP11," submitted to Molecular Cancer Research (hereafter referred to as the "Molecular Cancer Research manuscript"). ORI found that the Respondent knowingly falsified and/or fabricated Western
A formal finding of research misconduct under 42 CFR part 93 (HHS) or equivalent agency policy. The respondent was found to have engaged in fabrication, falsification, or plagiarism of research data. The federal grant funds involved are typically identified in the FR notice, along with the administrative actions (debarment, supervised research, manuscript correction or retraction requirements).